MIGLIETTA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.278
AS - Asia 371
EU - Europa 343
SA - Sud America 4
AF - Africa 1
Totale 2.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.277
SG - Singapore 159
IT - Italia 156
CN - Cina 146
FI - Finlandia 52
SE - Svezia 38
FR - Francia 25
HK - Hong Kong 23
GB - Regno Unito 22
DE - Germania 19
IN - India 18
VN - Vietnam 11
IE - Irlanda 8
CZ - Repubblica Ceca 7
PH - Filippine 6
MK - Macedonia 5
BR - Brasile 4
ES - Italia 4
BE - Belgio 3
JP - Giappone 3
IL - Israele 2
AL - Albania 1
CA - Canada 1
CH - Svizzera 1
EG - Egitto 1
HR - Croazia 1
IR - Iran 1
KR - Corea 1
KZ - Kazakistan 1
NL - Olanda 1
Totale 2.997
Salva come PNG Salva come JPEG
Città #
Fairfield 379
Chandler 281
Ashburn 198
Woodbridge 183
Houston 164
Cambridge 146
Seattle 139
Singapore 135
Ann Arbor 126
Wilmington 111
Padova 52
Helsinki 43
Beijing 37
San Diego 37
Medford 35
Princeton 35
Des Moines 27
Roxbury 27
Santa Clara 18
Boardman 16
Jinan 12
London 12
New York 12
Dong Ket 11
Milan 11
Nanjing 11
Dallas 10
Pune 10
Codogno 9
Rome 9
Dublin 8
Zhengzhou 8
Norwalk 7
Falls Church 6
Olomouc 6
Washington 6
Lappeenranta 5
Selvazzano Dentro 5
Shenyang 5
Skopje 5
Turin 5
Council Bluffs 4
Los Angeles 4
Barcelona 3
Brussels 3
Changsha 3
Chiswick 3
Guangzhou 3
Hamburg 3
Nanchang 3
Redwood City 3
Tianjin 3
Venice 3
Andrano 2
Avezzano 2
Bergamo 2
Capo d'Orlando 2
Clermont-Ferrand 2
Haikou 2
Hefei 2
Hong Kong 2
Hounslow 2
Lanzhou 2
Mabalacat 2
New Bedfont 2
Pasig 2
Perugia 2
Rehovot 2
Sale Marasino 2
Selargius 2
Sestu 2
Tokyo 2
Verona 2
Vimercate 2
Almaty 1
Apalit 1
Apiro 1
Cairo 1
Casalnuovo di Napoli 1
Costabissara 1
Decatur 1
Dongguan 1
Enschede 1
Falkenstein 1
Frankfurt am Main 1
Gunzenhausen 1
Iesi 1
Kilburn 1
Lower Saxony 1
Marana 1
Marche 1
Miami 1
Mountain View 1
Newark 1
Ningbo 1
Ogden 1
Phoenix 1
Prague 1
Prescot 1
Quezon City 1
Totale 2.468
Salva come PNG Salva come JPEG
Nome #
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 172
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 139
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 136
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 129
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 125
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 122
Immune characterization of breast cancer metastases: Prognostic implications 122
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 119
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 115
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 114
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 100
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 97
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 90
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 88
Abdominal Wall Reconstruction: Biomaterialsand Tissue Engineering Biomaterials 80
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 75
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 69
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 69
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 64
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 62
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 61
Evolution of HER2-low expression from primary to recurrent breast cancer 57
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 53
Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: A review of the current literature 53
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 49
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 46
Complicanze tromboemboliche in chirurgia plastica: osservazioni su 20000 procedure di chirurgia maggiore 45
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 42
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 39
Olaparib for advanced breast cancer 39
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 39
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 38
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 34
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 33
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 30
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 30
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 27
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 27
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 25
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications 24
HER2: a never ending story 22
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 19
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 19
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 19
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 18
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 17
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 17
An overview of immune checkpoint inhibitors in breast cancer 16
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 15
Breast cancer biological characterization - Evaluation of the prognostic and/or predictive role of clinical, pathological and molecular biomarkers to dissect breast cancer heterogeneity: focus on estrogen-low breast cancer 11
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 10
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 8
How can we refine the prognostic stratification of triple-negative breast cancer? 7
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 7
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 7
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 6
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 6
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 5
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 4
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 3
Totale 3.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.150
article - articoli 14.799
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 179
Totale 30.128
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020493 0 0 0 132 48 26 53 56 69 59 34 16
2020/2021590 14 33 28 24 16 113 45 49 72 107 48 41
2021/2022562 23 48 55 27 64 33 68 34 39 17 39 115
2022/2023556 93 70 35 68 54 59 20 28 88 3 30 8
2023/2024434 44 48 50 27 32 59 35 16 7 27 34 55
2024/2025268 1 150 71 46 0 0 0 0 0 0 0 0
Totale 3.114